Key points are not available for this paper at this time.
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Richard S. Finn
Shukui Qin
Masafumi Ikeda
New England Journal of Medicine
Harvard University
Massachusetts General Hospital
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Finn et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d6d84e8dca315383ed93a7 — DOI: https://doi.org/10.1056/nejmoa1915745